background and objective: esophageal cancer especially squamous cell carcinoma (scc) is one of the most common gastro intestinal malignancies in north part of iran (khorasan). the standard treatment for esophageal cancer is surgical resection, but its outcome remains poor. then, the oncologists try to treat this cancer with sandwich protocols especially neo-adjuvant chemo-radiotherapy. several ...

Surgical resection remains the standard of care for clini- cally localized renal cell carcinoma (RCC). Nearly 1 in 4 patients will have a recurrence after surgery performed with curative intent, and stand to benefit from additional therapy. Currently, no proven adjuvant or neoadjuvant therapies are available. A number of phase 3 adjuvant therapy trials are ongoing that are evaluating small-mole...

Assessment of respectability may be regarded as a key component esophageal cancer treatment. Neoadjuvant therapies considered particularly in the setting locally advanced cancer. While surgery alone adequate for selected patients, incorporation neoadjuvant or adjuvant therapeutic strategies with respect to patient, tumor, and treatment characteristics. In this study, we focused on tumor size ch...

Gastric adenocarcinoma is one of the most common causes of death worldwide. Surgical resection remains the mainstay of therapy, offering the only chance for complete cure. Resection is based on the principles of obtaining adequate margins, with the extent of lymphadenectomy remaining controversial. Neoadjuvant and adjuvant therapies are used to reduce local recurrence and improve long-term surv...

Neoadjuvant treatment of breast cancer initially was limited to patients with locally advanced breast cancer in which downstaging was necessary. Now, neoadjuvant trials have become an increasingly common way to facilitate the rapid assessment of new cancer therapies. The appeal of neoadjuvant trials is that they provide the opportunity to study translational science, tumor biomarkers, and inter...

Muscle-invasive bladder cancer (MIBC) is often framed as a systemic disease given the risk of occult metastases and clinical under-staging at time radical cystectomy. The current standard care for non-metastatic MIBC combines cisplatin-based neoadjuvant chemotherapy regimen followed by cystectomy, pelvic lymph node dissection, urinary reconstruction. Other therapies initially developed metastat...

OBJECTIVES Efforts to improve the clinical outcome for patients with localized high-risk prostate cancer have led to the development of neoadjuvant systemic therapies. We review the different modalities of neoadjuvant therapies for localized prostate cancer and highlight emerging treatment approaches including immunotherapy and targeted therapy. METHODS We performed a PubMed search of clinica...

There are currently no predictive biomarkers for long-term survival after neoadjuvant chemoimmunotherapy. However, the identification of non-small lung cancer (NSCLC) patients who obtain benefit from chemoimmunotherapy is essential to optimize therapies.

The use of neoadjuvant therapies has played a major role for borderline resectable and locally advanced pancreatic cancers (PCs). For this group of patients, preoperative chemotherapy or chemoradiation has increased the likelihood of surgery with negative resection margins and overall survival. On the other hand, for patients with resectable PC, the main rationale for neoadjuvant therapy is tha...